Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | PDE5A | O76074 | 9/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | GAK | O14976 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.34 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.34 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7344831 | 1.00 | AR (0.36) | ARPDE5AKDM1AGAKRIPK2 | |
| SCHEMBL7720296 | 0.76 | CA9 (0.46) | ARPDE5ANCEH1PDE4APDE4B | |
| SCHEMBL7725096 | 0.76 | AR (0.41) | ARPDE5AKDM1AGAKRIPK2 | |
| SCHEMBL7337530 | 0.73 | AR (0.46) | ARPDE5AKDM1AGAKRIPK2 | |
| SCHEMBL7344856 | 0.72 | AR (0.45) | ARPDE5AKDM1AGAKRIPK2 | |
| SCHEMBL7723749 | 0.70 | AR (0.50) | ARPDE5AKDM1AGAKRIPK2 | |
| SCHEMBL7723766 | 0.70 | AR (0.43) | ARPDE5AKDM1ASLC6A4ACHE | |
| SCHEMBL7341643 | 0.69 | AR (0.45) | ARPDE5AKDM1AGAKRIPK2 | |
| SCHEMBL7336198 | 0.69 | AR (0.45) | ARPDE5AKDM1AGAKRIPK2 | |
| SCHEMBL7724994 | 0.69 | CA1 (0.44) | ARPDE5ANCEH1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | AR 4226/4885PDE5A 2079/4885KDM1A 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.